A 59-year-old man comes to his family physician for follow-up of type 2 diabetes mellitus diagnosed 8 years ago. He takes metformin 1000 mg twice daily with good adherence. Two years ago he had a myocardial infarction and now has heart failure with a left ventricular ejection fraction of 35%; he takes carvedilol, sacubitril-valsartan, spironolactone, atorvastatin, and aspirin. He walks 30 minutes most days and does not smoke. His BMI is 31 kg/m2, pulse is 68/min, and blood pressure is 124/76 mm Hg. Examination shows trace ankle edema and clear lungs. Laboratory studies show hemoglobin A1c 8.2%, creatinine 1.2 mg/dL (estimated GFR 62 mL/min/1.73 m2), potassium 4.6 mEq/L, and urine albumin-to-creatinine ratio 60 mg/g. Which of the following is the most appropriate addition to his diabetes regimen?
- Glipizide
- Pioglitazone
- Sitagliptin
- Empagliflozin
- Insulin glargine
Show the answer and explanation
Correct answer: D. Empagliflozin
For a patient with type 2 diabetes and established heart failure with reduced ejection fraction, an SGLT2 inhibitor is recommended independent of A1c because it reduces heart failure hospitalization and cardiovascular death and slows progression of chronic kidney disease (he also has albuminuria). Empagliflozin, dapagliflozin, and canagliflozin have demonstrated these benefits, and eGFR above 20-25 mL/min/1.73 m2 permits initiation. Thiazolidinediones cause fluid retention and are contraindicated in symptomatic heart failure; sulfonylureas, DPP-4 inhibitors, and basal insulin lower glucose without cardiovascular benefit, and saxagliptin increases heart failure hospitalization.
Why each option is right or wrong
- GlipizideSulfonylureas lower glucose but cause hypoglycemia and weight gain and confer no cardiovascular or renal benefit.
- PioglitazonePioglitazone causes sodium retention and edema and is contraindicated in patients with heart failure.
- SitagliptinDPP-4 inhibitors are weight-neutral but offer no cardiovascular protection, and some (saxagliptin) worsen heart failure outcomes.
- EmpagliflozinCorrect: SGLT2 inhibitors reduce heart failure hospitalization, cardiovascular death, and CKD progression in type 2 diabetes with HFrEF.
- Insulin glargineBasal insulin is effective for glycemia but is not preferred before agents with proven cardiorenal benefit at this A1c.
Type 2 diabetes with heart failure or CKD: add an SGLT2 inhibitor regardless of A1c; with ASCVD, an SGLT2 inhibitor or GLP-1 receptor agonist; avoid thiazolidinediones in heart failure.
References
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes 2026 (American Diabetes Association (PMC12690185))